TY - JOUR
T1 - Identification of a novel chemokine-dependent molecular mechanism underlying Rheumatoid arthritisassociated autoantibody-mediated bone loss
AU - Krishnamurthy, Akilan
AU - Joshua, Vijay
AU - Hensvold, Aase Haj
AU - Jin, Tao
AU - Sun, Meng
AU - Vivar, Nancy
AU - Ytterberg, A. Jimmy
AU - Engström, Marianne
AU - Fernandes-Cerqueira, Cátia
AU - Amara, Khaled
AU - Magnusson, Malin
AU - Wigerblad, Gustaf
AU - Kato, Jungo
AU - Jiménez-Andrade, Juan Miguel
AU - Tyson, Kerry
AU - Rapecki, Stephen
AU - Lundberg, Karin
AU - Catrina, Sergiu Bogdan
AU - Jakobsson, Per Johan
AU - Svensson, Camilla
AU - Malmström, Vivianne
AU - Klareskog, Lars
AU - Wähämaa, Heidi
AU - Catrina, Anca I.
N1 - Funding Information:
This work was supported by the Swedish Research Council, FP7-HEALTH-2012 INNOVATION-1 Euro-TEAM (305549-2), the Initial Training Networks 7th framework programme Osteoimmune (289150), and Innovative Medicine Initiative BTCure (115142-2) and through the Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet.
PY - 2016/4
Y1 - 2016/4
N2 - Objectives: Rheumatoid arthritis (RA)-specific anticitrullinated protein/peptide antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of ACPAs in osteoclast (OC) activation and to identify key cellular mediators in this process. Methods: Polyclonal ACPA were isolated from the synovial fluid (SF) and peripheral blood of patients with RA. Monoclonal ACPAs were isolated from single SF B-cells of patients with RA. OCs were developed from blood cell precursors with or without ACPAs. We analysed expression of citrullinated targets and peptidylarginine deiminases (PAD) enzymes by immunohistochemistry and cell supernatants by cytometric bead array. The effect of an anti-interleukin (IL)-8 neutralising antibody and a pan-PAD inhibitor was tested in the OC cultures. Monoclonal ACPAs were injected into mice and bone structure was analysed by micro-CT before and after CXCR1/2 blocking with reparixin. Results: Protein citrullination by PADs is essential for OC differentiation. Polyclonal ACPAs enhance OC differentiation through a PAD-dependent IL-8-mediated autocrine loop that is completely abolished by IL-8 neutralisation. Some, but not all, human monoclonal ACPAs derived from single SF B-cells of patients with RA and exhibiting distinct epitope specificities promote OC differentiation in cell cultures. Transfer of the monoclonal ACPAs into mice induced bone loss that was completely reversed by the IL-8 antagonist reparixin. Conclusions: We provide novel insights into the key role of citrullination and PAD enzymes during OC differentiation and ACPA-induced OC activation. Our findings suggest that IL8-dependent OC activation may constitute an early event in the initiation of the joint specific inflammation in ACPA-positive RA.
AB - Objectives: Rheumatoid arthritis (RA)-specific anticitrullinated protein/peptide antibodies (ACPAs) appear before disease onset and are associated with bone destruction. We aimed to dissect the role of ACPAs in osteoclast (OC) activation and to identify key cellular mediators in this process. Methods: Polyclonal ACPA were isolated from the synovial fluid (SF) and peripheral blood of patients with RA. Monoclonal ACPAs were isolated from single SF B-cells of patients with RA. OCs were developed from blood cell precursors with or without ACPAs. We analysed expression of citrullinated targets and peptidylarginine deiminases (PAD) enzymes by immunohistochemistry and cell supernatants by cytometric bead array. The effect of an anti-interleukin (IL)-8 neutralising antibody and a pan-PAD inhibitor was tested in the OC cultures. Monoclonal ACPAs were injected into mice and bone structure was analysed by micro-CT before and after CXCR1/2 blocking with reparixin. Results: Protein citrullination by PADs is essential for OC differentiation. Polyclonal ACPAs enhance OC differentiation through a PAD-dependent IL-8-mediated autocrine loop that is completely abolished by IL-8 neutralisation. Some, but not all, human monoclonal ACPAs derived from single SF B-cells of patients with RA and exhibiting distinct epitope specificities promote OC differentiation in cell cultures. Transfer of the monoclonal ACPAs into mice induced bone loss that was completely reversed by the IL-8 antagonist reparixin. Conclusions: We provide novel insights into the key role of citrullination and PAD enzymes during OC differentiation and ACPA-induced OC activation. Our findings suggest that IL8-dependent OC activation may constitute an early event in the initiation of the joint specific inflammation in ACPA-positive RA.
UR - http://www.scopus.com/inward/record.url?scp=84961966554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961966554&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2015-208093
DO - 10.1136/annrheumdis-2015-208093
M3 - Article
C2 - 26612338
AN - SCOPUS:84961966554
SN - 0003-4967
VL - 75
SP - 721
EP - 729
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 4
ER -